Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Lisa Astor
Advertisement
Articles by Lisa Astor
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
4
Leveraging Novel Software to Further Improve Personalized Cancer Care
5
